Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
暂无分享,去创建一个
P. Cowen | A. Cipriani | E. Turner | K. Hawton | R. McShane | Erick H Turner | S. Spyridi | R. Dean | Claudia C. Hurducas | Sarah Hollingsworth | Tahnee Marquardt | A. Barnes | Rebecca Smith
[1] W. Marcantoni,et al. A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009 - January 2019. , 2020, Journal of affective disorders.
[2] W. Drevets,et al. Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II) , 2020, The international journal of neuropsychopharmacology.
[3] S. Naveed,et al. Effectiveness and Safety of Ketamine for Unipolar Depression: a Systematic Review , 2020, Psychiatric Quarterly.
[4] U. Mehta,et al. Antidepressant effects of ketamine and ECT: A pilot comparison. , 2020, Journal of Affective Disorders.
[5] E. Ballard,et al. The effects of ketamine on typical and atypical depressive symptoms , 2020, Acta psychiatrica Scandinavica.
[6] P. Fontoura,et al. Randomized, Double-Blind, Placebo-Controlled Trial of the mGlu2/3 Negative Allosteric Modulator Decoglurant in Partially Refractory Major Depressive Disorder. , 2020, The Journal of clinical psychiatry.
[7] N. Malhotra,et al. Comparison of efficacy of ketamine versus thiopentone-assisted modified electroconvulsive therapy in major depression , 2020, Indian journal of psychiatry.
[8] P. Cuijpers,et al. Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis. , 2020, The lancet. Psychiatry.
[9] Christopher R. Erbes,et al. A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression , 2020, Translational Psychiatry.
[10] S. Kennedy,et al. A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (CAN-BIND) study protocol , 2020, BMC Psychiatry.
[11] P. Svenningsson,et al. A randomized placebo-controlled PET study of ketamine´s effect on serotonin1B receptor binding in patients with SSRI-resistant depression , 2020, Translational Psychiatry.
[12] Cheng-Ta Li,et al. Efficacy of low-dose ketamine infusion in anxious vs nonanxious depression: revisiting the Adjunctive Ketamine Study of Taiwanese Patients with Treatment-Resistant Depression , 2020, CNS Spectrums.
[13] Xiang Li,et al. Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I). , 2020, The Journal of clinical psychiatry.
[14] J. Ioannidis,et al. Generating comparative evidence on new drugs and devices after approval , 2020, The Lancet.
[15] Andrea Cipriani,et al. Generating comparative evidence on new drugs and devices before approval , 2020, The Lancet.
[16] Jie Luo,et al. Effects of Low-Dose Ketamine on the Antidepressant Efficacy and Suicidal Ideations in Patients Undergoing Electroconvulsive Therapy. , 2020, The journal of ECT.
[17] K. Sim,et al. Adjunctive intranasal esketamine for major depressive disorder: A systematic review of randomized double-blind controlled-placebo studies. , 2020, Journal of affective disorders.
[18] L. Aftanas,et al. Placebo-controlled study of xenon effect on the emotions and frequency of the EEG alpha-oscillations , 2019 .
[19] M. Jacobson,et al. P.601 AXS-05 (dextromethorphan/bupropion), a novel, oral, investigational agent for major depressive disorder: Results of a randomized, double-blind, active-controlled, multi-center trial (ASCEND) , 2019, European Neuropsychopharmacology.
[20] Cheng-Ta Li,et al. Antidepressant and antisuicidal effects of ketamine on the functional connectivity of prefrontal cortex-related circuits in treatment-resistant depression: A double-blind, placebo-controlled, randomized, longitudinal resting fMRI study. , 2019, Journal of affective disorders.
[21] C. Loo,et al. Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study. , 2019, Journal of affective disorders.
[22] E. Turner,et al. Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval. , 2019, The lancet. Psychiatry.
[23] W. Drevets,et al. Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3. , 2019, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[24] K. Sim,et al. Brexanolone for postpartum depression: A meta-analysis of randomized controlled studies , 2019, Psychiatry Research.
[25] O. Efthimiou. Statistics in pills: meta-analysis of rare events , 2019, Evidence-Based Mental Health.
[26] M. Fava,et al. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1) , 2019, The international journal of neuropsychopharmacology.
[27] J. Rosenblat. Potential differences in antidepressant effects of oral ketamine liquid suspension versus compounded capsules , 2019, The British Journal of Psychiatry.
[28] T. Outhred,et al. Getting irritable about irritability? , 2019, Evidence-Based Mental Health.
[29] R. Shelton,et al. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. , 2019, The American journal of psychiatry.
[30] Chun-Hsin Chen,et al. Lamotrigine augmentation in treatment-resistant unipolar depression: A comprehensive meta-analysis of efficacy and safety , 2019, Journal of psychopharmacology.
[31] A. Cipriani,et al. Barriers and incentives to recruitment in mental health clinical trials , 2019, Evidence-Based Mental Health.
[32] J. Krystal,et al. Association of Combined Naltrexone and Ketamine With Depressive Symptoms in a Case series of Patients With Depression and Alcohol Use Disorder , 2019, JAMA psychiatry.
[33] F. Clement,et al. Current and Common Definitions of Treatment-Resistant Depression: Findings from a Systematic Review and Qualitative Interviews , 2019, Canadian journal of psychiatry. Revue canadienne de psychiatrie.
[34] S. Wilkinson,et al. A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems. , 2019, Drug discovery today.
[35] D. Mavridis,et al. Reasoning under uncertainty , 2019, Evidence-Based Mental Health.
[36] A. Cipriani,et al. Providing the most appropriate care to our individual patients , 2019, Evidence-Based Mental Health.
[37] E. Brown,et al. Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial. , 2019, Journal of affective disorders.
[38] W. Drevets,et al. Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. , 2019, Focus.
[39] S. Southwick,et al. Rapamycin, an Immunosuppressant and mTORC1 Inhibitor, Triples the Antidepressant Response Rate of Ketamine at 2 Weeks Following Treatment: A double-blind, placebo-controlled, cross-over, randomized clinical trial , 2018 .
[40] M. Mimura,et al. Glutamatergic neurometabolite levels in major depressive disorder: a systematic review and meta-analysis of proton magnetic resonance spectroscopy studies , 2018, Molecular Psychiatry.
[41] C. W. Carspecken,et al. Ketamine Anesthesia Does Not Improve Depression Scores in Electroconvulsive Therapy: A Randomized Clinical Trial , 2018, Journal of neurosurgical anesthesiology.
[42] S. Muthukumaraswamy,et al. Differences in excitatory and inhibitory neurotransmitter levels between depressed patients and healthy controls: A systematic review and meta-analysis. , 2018, Journal of psychiatric research.
[43] Teddy J. Akiki,et al. Ketamine, but Not the NMDAR Antagonist Lanicemine, Increases Prefrontal Global Connectivity in Depressed Patients , 2018, Chronic stress.
[44] M. Fava,et al. Double-Blind, Placebo-Controlled, Dose-Ranging Trial of Intravenous Ketamine as Adjunctive Therapy in Treatment-Resistant Depression (TRD) , 2018, Molecular Psychiatry.
[45] D. M. Lyons,et al. Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism. , 2018, The American journal of psychiatry.
[46] A. Ghajar,et al. Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-blind controlled trial. , 2018, Journal of affective disorders.
[47] W. Drevets,et al. S114. Efficacy and Safety of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression , 2018, Biological Psychiatry.
[48] P. Mitchell,et al. Repeated intranasal ketamine for treatment-resistant depression – the way to go? Results from a pilot randomised controlled trial , 2018, Journal of psychopharmacology.
[49] W. Tam,et al. Prevalence of Depression in the Community from 30 Countries between 1994 and 2014 , 2018, Scientific Reports.
[50] R. Rosenheck,et al. A randomized clinical trial of adjunctive ketamine anesthesia in electro-convulsive therapy for depression. , 2018, Journal of affective disorders.
[51] R. Shelton,et al. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial , 2017, JAMA psychiatry.
[52] P. Cowen,et al. Brain glutamate in medication-free depressed patients: a proton MRS study at 7 Tesla , 2017, Psychological Medicine.
[53] M. Milak,et al. Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial. , 2017, The American journal of psychiatry.
[54] C. Stewart,et al. Ketamine as the anaesthetic for electroconvulsive therapy: the KANECT randomised controlled trial , 2017, British Journal of Psychiatry.
[55] H. Meng,et al. Effect of Low Dose of Ketamine on Learning Memory Function in Patients Undergoing Electroconvulsive Therapy—A Randomized, Double-Blind, Controlled Clinical Study , 2017, The journal of ECT.
[56] John H Krystal,et al. Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with Treatment-Resistant Depression , 2017, Neuropsychopharmacology.
[57] G. Dunn,et al. Ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT): a multicentre, double-blind, randomised, parallel-group, superiority trial , 2017, The lancet. Psychiatry.
[58] M. Zarrindast,et al. Effect of memantine combination therapy on symptoms in patients with moderate‐to‐severe depressive disorder: randomized, double‐blind, placebo‐controlled study , 2017, Journal of clinical pharmacy and therapeutics.
[59] Benjamin Boche,et al. A Double-Blinded, Randomized, Placebo-Controlled Sub-Dissociative Dose Ketamine Pilot Study in the Treatment of Acute Depression and Suicidality in a Military Emergency Department Setting. , 2016, Military medicine.
[60] C. Normann,et al. Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials , 2016, CNS Spectrums.
[61] Michael R. Johnson,et al. Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study , 2016, Neuropsychopharmacology.
[62] Husseini Manji,et al. Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study , 2016, Biological Psychiatry.
[63] X. Zhong,et al. Mood and neuropsychological effects of different doses of ketamine in electroconvulsive therapy for treatment-resistant depression. , 2016, Journal of affective disorders.
[64] P. Fontoura,et al. Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial. , 2016, JAMA psychiatry.
[65] G. Dawson,et al. Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulate , 2016, European Neuropsychopharmacology.
[66] R. Shelton,et al. A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. , 2016, The American journal of psychiatry.
[67] S. Akhondzadeh,et al. Riluzole combination therapy for moderate-to-severe major depressive disorder: A randomized, double-blind, placebo-controlled trial. , 2016, Journal of psychiatric research.
[68] Bang-Hung Yang,et al. The effects of low‐dose ketamine on the prefrontal cortex and amygdala in treatment‐resistant depression: A randomized controlled study , 2016, Human brain mapping.
[69] G. Ungvari,et al. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study , 2015, Psychological Medicine.
[70] A. Mohammadbeigi,et al. Impact comparison of ketamine and sodium thiopental on anesthesia during electroconvulsive therapy in major depression patients with drug-resistant; a double-blind randomized clinical trial , 2015, Annals of cardiac anaesthesia.
[71] L. Tamam,et al. Effect of Ketamine, Thiopental and Ketamine-Thiopental Combination during Electroconvulsive Therapy for Depression. , 2015, Turkish journal of anaesthesiology and reanimation.
[72] J. Rendell,et al. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults , 2015, BJPsych Advances.
[73] T. Furukawa,et al. Ketamine and other glutamate receptor modulators for depression in adults , 2015, BJPsych Advances.
[74] F. Gharibi,et al. Antidepressant Effect of Combined Ketamine and Electroconvulsive Therapy on Patients With Major Depressive Disorder: A Randomized Trial , 2015, Iranian journal of psychiatry and behavioral sciences.
[75] S. Dabir,et al. Memantine in the prevention or alleviation of electroconvulsive therapy induces cognitive disorders: A placebo controlled trial. , 2015, Asian journal of psychiatry.
[76] K. Laws,et al. The use of ketamine as an antidepressant: a systematic review and meta‐analysis , 2015, Human psychopharmacology.
[77] F. Erdil,et al. Effects of sevoflurane or ketamine on the QTc interval during electroconvulsive therapy , 2015, Journal of Anesthesia.
[78] D. Charney,et al. Neurocognitive Effects of Ketamine and Association with Antidepressant Response in Individuals with Treatment-Resistant Depression: A Randomized Controlled Trial , 2015, Neuropsychopharmacology.
[79] S. Preskorn,et al. Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. , 2015, Journal of psychiatric practice.
[80] D. Charney,et al. A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder , 2014, Biological Psychiatry.
[81] J. Beck,et al. Fast BDNF serum level increase and diurnal BDNF oscillations are associated with therapeutic response after partial sleep deprivation. , 2014, Journal of psychiatric research.
[82] R. Lam,et al. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes , 2014, Psychological Medicine.
[83] Dimitris Mavridis,et al. Addressing missing outcome data in meta-analysis , 2014, Evidence-Based Mental Health.
[84] D. Kupfer,et al. A proposal for an updated neuropsychopharmacological nomenclature , 2014, European Neuropsychopharmacology.
[85] M. Berk,et al. The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial. , 2014, The Journal of clinical psychiatry.
[86] E. Shirzadi,et al. Memantine add on to citalopram in elderly patients with depression: A double-blind placebo-controlled study , 2014, Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences.
[87] John R Geddes,et al. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic , 2014, Journal of psychopharmacology.
[88] S. Shergill,et al. Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy , 2014, Therapeutic advances in psychopharmacology.
[89] D. Charney,et al. EFFECTS OF KETAMINE ON EXPLICIT AND IMPLICIT SUICIDAL COGNITION: A RANDOMIZED CONTROLLED TRIAL IN TREATMENT‐RESISTANT DEPRESSION , 2014, Depression and anxiety.
[90] S. Akhondzadeh,et al. Comparing Effects of Ketamine and Thiopental Administration During Electroconvulsive Therapy in Patients With Major Depressive Disorder: A Randomized, Double-Blind Study , 2014, The journal of ECT.
[91] T. Dinan,et al. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. , 2014, Journal of affective disorders.
[92] J. P. Abenstein,et al. A randomized comparison of ketamine versus methohexital anesthesia in electroconvulsive therapy , 2014, Psychiatry Research.
[93] M. Ghasemi,et al. Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder , 2014, Psychiatry Research.
[94] Yue-Cune Chang,et al. Inhibition of Glycine Transporter-I as a Novel Mechanism for the Treatment of Depression , 2013, Biological Psychiatry.
[95] M. Quirk,et al. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects , 2013, Molecular Psychiatry.
[96] Eric G. Smith,et al. Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial. , 2013, The Journal of clinical psychiatry.
[97] D. Charney,et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. , 2013, The American journal of psychiatry.
[98] A. Cipriani,et al. Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials. , 2013, The British journal of psychiatry : the journal of mental science.
[99] A. Yli-Hankala,et al. Effects of S-Ketamine as an Anesthetic Adjuvant to Propofol on Treatment Response to Electroconvulsive Therapy in Treatment-Resistant Depression: A Randomized Pilot Study , 2013, The journal of ECT.
[100] D. Luckenbaugh,et al. A Randomized Trial of a Low-Trapping Nonselective N-Methyl-D-Aspartate Channel Blocker in Major Depression , 2013, Biological Psychiatry.
[101] Andrea Cipriani,et al. Fluoxetine versus other types of pharmacotherapy for depression. , 2013, The Cochrane database of systematic reviews.
[102] E. Walker,et al. Diagnostic and Statistical Manual of Mental Disorders , 2013 .
[103] D. Javitt,et al. A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression. , 2013, The international journal of neuropsychopharmacology.
[104] C. Loo,et al. Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial. , 2012, Journal of affective disorders.
[105] R. Bursi,et al. Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: an exploratory, randomized, double-blind, placebo-controlled trial , 2012, Journal of psychopharmacology.
[106] D. Luckenbaugh,et al. A Randomized, Placebo-Controlled, Crossover Pilot Trial of the Oral Selective NR2B Antagonist MK-0657 in Patients With Treatment-Resistant Major Depressive Disorder , 2012, Journal of clinical psychopharmacology.
[107] D. Luckenbaugh,et al. Course of Improvement in Depressive Symptoms to a Single Intravenous Infusion of Ketamine vs Add-on Riluzole: Results from a 4-Week, Double-Blind, Placebo-Controlled Study , 2012, Neuropsychopharmacology.
[108] J. Krystal,et al. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS , 2011, Psychiatry Research: Neuroimaging.
[109] G. Hasler,et al. PATHOPHYSIOLOGY OF DEPRESSION: DO WE HAVE ANY SOLID EVIDENCE OF INTEREST TO CLINICIANS? , 2010, World psychiatry : official journal of the World Psychiatric Association.
[110] Nanxin Li,et al. mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists , 2010, Science.
[111] J. Higgins,et al. Cochrane Handbook for Systematic Reviews of Interventions , 2010, International Coaching Psychology Review.
[112] S. Irwin,et al. Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care. , 2010, Journal of palliative medicine.
[113] Rachel Churchill,et al. Mirtazapine versus other antidepressive agents for depression. , 2010, The Cochrane database of systematic reviews.
[114] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.
[115] N. Kerse,et al. Antidepressants versus placebo for depression in primary care. , 2009, The Cochrane database of systematic reviews.
[116] J. Geddes,et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis , 2009, The Lancet.
[117] A. Borgeat,et al. Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression , 2009, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.
[118] M. Krams,et al. An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive Disorder , 2008, Journal of clinical psychopharmacology.
[119] N. Watanabe,et al. Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: systematic review and meta-analysis. , 2008, The Journal of clinical psychiatry.
[120] T. Furukawa,et al. Evidence-based guidelines for interpretation of the Hamilton Rating Scale for Depression. , 2007, Journal of clinical psychopharmacology.
[121] J. Amsterdam,et al. Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study. , 2007, The Journal of clinical psychiatry.
[122] G. Guyatt,et al. Association between unreported outcomes and effect size estimates in Cochrane meta-analyses. , 2007, JAMA.
[123] D. Stein,et al. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? , 2006, The Journal of clinical psychiatry.
[124] Paul J Carlson,et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. , 2006, Archives of general psychiatry.
[125] D. Javitt,et al. Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder. , 2006, Journal of affective disorders.
[126] J. Endicott,et al. Quality-of-life impairment in depressive and anxiety disorders. , 2005, The American journal of psychiatry.
[127] E. Huey,et al. Development of subtle psychotic symptoms with memantine: a case report. , 2005, The Journal of clinical psychiatry.
[128] T. Furukawa,et al. Imputing response rates from means and standard deviations in meta-analyses , 2005, International clinical psychopharmacology.
[129] G. Guyatt,et al. Grading quality of evidence and strength of recommendations , 2004, BMJ : British Medical Journal.
[130] Sara T Brookes,et al. Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test. , 2004, Journal of clinical epidemiology.
[131] Hubertus Himmerich,et al. Differentiating moderate and severe depression using the Montgomery-Asberg depression rating scale (MADRS). , 2003, Journal of affective disorders.
[132] Gordon H Guyatt,et al. Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses. , 2002, International journal of epidemiology.
[133] Douglas G Altman,et al. Meta-analyses involving cross-over trials: methodological issues. , 2002, International journal of epidemiology.
[134] R. Kerwin,et al. Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. , 2001, Archives of general psychiatry.
[135] J. Sterne,et al. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. , 2000, Journal of clinical epidemiology.
[136] R. Hirschfeld. History and evolution of the monoamine hypothesis of depression. , 2000, The Journal of clinical psychiatry.
[137] C. Eap,et al. Fluoxetine augmentation in citalopram non-responders: pharmacokinetic and clinical consequences. , 2000, The international journal of neuropsychopharmacology.
[138] John H Krystal,et al. Antidepressant effects of ketamine in depressed patients , 2000, Biological Psychiatry.
[139] R. Croyle,et al. The new genetics: Psychological responses to genetic testing , 1998 .
[140] G. Smith,et al. Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.
[141] J. Gallo,et al. Symptom profiles of depression among general medical service users compared with speciality mental health service users , 1997, Psychological Medicine.
[142] D G Altman,et al. Statistics Notes: Detecting skewness from summary information , 1996, BMJ.
[143] W. Nolen,et al. Benzodiazepines for depression? A review of the literature. , 1995, International clinical psychopharmacology.
[144] F. Petty,et al. Plasma GABA levels in psychiatric illness. , 1984, Journal of affective disorders.
[145] M. Åsberg,et al. A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.
[146] E. Robins,et al. Research diagnostic criteria: rationale and reliability. , 1978, Archives of general psychiatry.
[147] A. Coppen. The Biochemistry of Affective Disorders , 1967, British Journal of Psychiatry.
[148] M. Hamilton. A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.
[149] Suicide , 1823, The Medico-Chirurgical Review and Journal of Medical Science. Analytical Series..
[150] S. Muthukumaraswamy,et al. Ketamine Enhances Visual Sensory Evoked Potential Long-term Potentiation in Patients With Major Depressive Disorder. , 2019, Biological psychiatry. Cognitive neuroscience and neuroimaging.
[151] Cheng-Ta Li,et al. Persistent antidepressant effect of low-dose ketamine and activation in the supplementary motor area and anterior cingulate cortex in treatment-resistant depression: A randomized control study. , 2018, Journal of affective disorders.
[152] S. Akhondzadeh,et al. Citicoline Combination Therapy for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial , 2017, Clinical neuropharmacology.
[153] L. S. Too,et al. Essentials of Global Mental Health: Suicide and depression , 2014 .
[154] J. Horáček,et al. Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression. , 2013, Neuro endocrinology letters.
[155] T. Furukawa,et al. Duloxetine versus other anti-depressive agents for depression. , 2012, The Cochrane database of systematic reviews.
[156] Harold Alan Pincus,et al. Reducing the Societal Burden of Depression , 2012, PharmacoEconomics.
[157] T. Furukawa,et al. Sertraline versus other antidepressive agents for depression. , 2010, The Cochrane database of systematic reviews.
[158] H. Ruhé,et al. Dose-escalation in the picture : pharmacological and imaging studies in depression , 2008 .
[159] D. Luckenbaugh,et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. , 2006, The American journal of psychiatry.
[160] Andrea Cipriani,et al. Imputing missing standard deviations in meta-analyses can provide accurate results. , 2006, Journal of clinical epidemiology.
[161] S. Strakowski,et al. The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review. , 2004, Journal of child and adolescent psychopharmacology.
[162] T. Peters,et al. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. , 2001, Health technology assessment.
[163] J. Feighner,et al. Diagnostic criteria for use in psychiatric research. , 1972, Archives of general psychiatry.